Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01136655 · ClinicalTrials.gov registry record · Phase 2
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01136655 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 54 participants.
The verdict
NCT01136655, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.
Interventions
- DRUG 80/2.25 μg Symbicort pMDI
- DRUG 80/4.5 μg Symbicort pMDI
- DRUG Foradil Aerolizer 12 μg
- DRUG 40 μg budesonide HFA pMDI
- DRUG placebo HFA pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01136655
The ClinicalTrials.gov registry entry for NCT01136655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 80/2.25 μg Symbicort pMDI is the first listed.
NCT01136655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01136655 about?
NCT01136655 is a clinical study titled "A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy". This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.
What is the current status of trial NCT01136655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2010-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01136655?
The interventions under investigation include: 80/2.25 μg Symbicort pMDI (DRUG), 80/4.5 μg Symbicort pMDI (DRUG), Foradil Aerolizer 12 μg (DRUG), 40 μg budesonide HFA pMDI (DRUG), placebo HFA pMDI (DRUG).
Who is sponsoring clinical trial NCT01136655?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.